Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Mar 22, 2011 SOUTH SAN FRANCISCO, Calif., March 22, 2011 – Achaogen, Inc., a biopharmaceutical company discovering and developing antibiotics for the treatment of life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the hiring of Kenneth J. Hillan, M.B. Ch.B., as chief medical officer. Dr. Hillan will fill a ...
Sep 9, 2010 SOUTH SAN FRANCISCO, Calif., September 9, 2010 – Achaogen, a biopharmaceutical company and developing antibiotics to treat life-threatening, multi-drug resistant (MDR), today announced key upcoming data presentations involving its lead antibiotic ...
Aug 30, 2010 SOUTH SAN FRANCISCO, Calif., August 30, 2010 – Achaogen, a biopharmaceutical company discovering and developing innovative antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the award of a contract with The Biomedical Advanced Research and Development Authority (BARDA), wit...
Apr 7, 2010 SAN FRANCISCO, Calif., April 7 , 2010 – Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the completion of a $56 million Series C round of financing. The round was ...
Sep 14, 2009 SAN FRANCISCO, CA, September 14, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug ca...
Aug 25, 2009 San Francisco, CA, August 25, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, announced today the appointment of John C. Doyle to the newly created position of chief op...
Jun 30, 2009 San Francisco, CA, June 30, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today that it has been selected as one of the annual FierceBiotech “Fierce 15...
May 16, 2009 SAN FRANCISCO, UNITED STATES and HELSINKI, FINLAND, May 16, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today the presentation of research on aminoglycosid...
Mar 23, 2009 SAN FRANCISCO, CA, March 23, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific of...
Mar 10, 2009 SAN FRANCISCO, CA, March 10, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific of...
Page: FirstPrevious ...
12
NextLast
= add release to Briefcase